Related Experiment Video
Updated: May 27, 2026
10:48
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Experience with carbon ion radiotherapy for WHO Grade 2 diffuse astrocytomas
Azusa Hasegawa1, Jun-Etsu Mizoe, Hirohiko Tsujii
1Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan.
International Journal of Radiation Oncology, Biology, Physics
|November 23, 2011
Summary
High-dose carbon ion radiotherapy significantly improved progression-free survival (PFS) and overall survival (OS) for adult diffuse astrocytomas. Both low- and high-dose treatments demonstrated acceptable toxicity profiles in this clinical trial.
Area of Science:
- Oncology
- Radiation Oncology
- Neuro-oncology
Background:
- Diffuse astrocytomas are challenging brain tumors requiring effective treatment strategies.
- Carbon ion radiotherapy offers a precise radiation delivery method with potential for improved outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of carbon ion radiotherapy for adult diffuse astrocytomas.
- To determine optimal radiation dosing for this patient population.
Main Methods:
- A phase I/II clinical trial involving 14 adult patients with diffuse astrocytoma.
- Carbon ion radiotherapy administered in 24 fractions over 6 weeks with dose escalation.
- Patients stratified into low-dose (46.2-50.4 GyE) and high-dose (55.2 GyE) groups.
Main Results:
- No Grade 3 or higher acute or late toxicities observed, indicating acceptable safety.
- Median progression-free survival (PFS) was 18 months (low-dose) vs. 91 months (high-dose) (p=0.0030).
- Median overall survival (OS) was 28 months (low-dose) vs. not reached (high-dose) (p=0.0208).
Conclusions:
- Higher doses of carbon ion radiotherapy significantly enhance PFS and OS in adult diffuse astrocytomas.
- Carbon ion radiotherapy is a safe and effective treatment option for diffuse astrocytomas.
- Further research into dose optimization for carbon ion radiotherapy is warranted.
